Table 3.
β-lactam plus BLI combinations registered for clinical use in Europe or in clinical evaluation for the treatment of several infections.
| Drugs and Dosage | Clinical Use | Therapeutic Indications (Duration of Treatment) |
Pediatric Use | Ref. |
|---|---|---|---|---|
| CAZ/AVI 1 2/0.5 g q8h 2-h IV infusion |
YES | cIAI (5–14 days) cUTI (5–10 days) Pyelonephritis (5–10 days) HAP (7–14 days) VAP (7–14 days) Aerobic G- infections (variable) |
YES (age ≥3 months) |
[45] |
| MER/VAB 2/2 g q8h 3-h IV infusion |
YES | cIAI (5–10 days) cUTI (5–10 days) Pyelonephritis (5–10 days) HAP (7–14 days) VAP (7–14 days) Aerobic G- infections (variable) Bacteremia (variable) |
NO | [50] |
| REL/IMI/CIL 0.25/0.5/0.5 g q6h 0.5-h IV infusion |
YES | HAP (7–14 days) VAP (7–14 days) Infections from Aerobic G- (variable) Bacteremia (variable) |
NO | [51] |
| REL/IMI 0.25/0.5 g q6h 0.5-h IV infusion |
NO | HAP (variable) VAP (variable) cUTI (variable) cIAI (variable) |
- | [100,101,102] |
| DUR/SUL | NO | Phase III studies: cUTI, HAP, VAP | - | [103,104] |
| DUR/IMI/CIL | NO | Studies in HV | - | [61] |
| ZID/CEF | NO | Phase III studies: cUTI, HAP, VAP | - | [104] |
| NAC/CEF or AZT | NO | Phase I studies: cUTI | - | [104] |
| TAN/CEF | NO | Phase III studies: cUTI | - | [104] |
1 Abbreviations: AVI, avibactam; AZT, aztreonam; CAZ, ceftazidime; CEF, cefepime; DUR, durlobactam; IMI, imipenem; IMI / CIL, imipenem/cilastatin; MER, meropenem; REL, relebactam; SUL, sulbactam; VAB, vaborbactam; cIAI, complicated intra-abdominal infection; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; VAP, ventilator-associated pneumonia; HV, healthy volunteers; IV; intravenous.